Section 1 of 6
Terms and abbreviations
1 evidence topic · 0 sources
| Abbreviation | Term |
|---|---|
| 4DMT | 4D Molecular Therapeutics |
| AAO | American Academy of Ophthalmology |
| AAV | Adeno-associated virus |
| ADL | Activities of daily living |
| AESI | Adverse event of special interest |
| AFLB | Aflibercept |
| AH | Aqueous humor |
| AHFS | American Hospital Formulary Service |
| AMD | Age-related macular degeneration |
| ANOVA | Analysis of variance |
| ANZ | Australia and New Zealand |
| APAC | Asia-Pacific |
| ARMS2 | Age-related maculopathy susceptibility 2 gene |
| ASP | Average sales price |
| ATC | Anatomical Therapeutic Chemical classification system |
| BCVA | Best corrected visual acuity |
| BLA | Biologics License Application |
| BLQ | Below the limit of quantitation |
| CBS | Charles Bonnet syndrome |
| CDMO | Contract development and manufacturing organization |
| CES-D-10 | Center for Epidemiologic Studies Depression Scale, 10-item version |
| CFH | Complement factor H gene |
| CI | Confidence interval |
| CMC | Chemistry, manufacturing, and controls |
| CMS | Centers for Medicare & Medicaid Services |
| CNV | Choroidal neovascularization |
| COGS | Cost of goods sold |
| CPT | Current Procedural Terminology |
| CRA | Caregiver Reaction Assessment |
| CrI | Credible interval |
| CRT | Central retinal thickness |
| CST | Central subfield thickness |
| CTIS | Clinical Trials Information System |
| CUR | Cost-utility ratio |
| DALY | Disability-adjusted life year |
| DCF | Discounted cash flow |
| DME | Diabetic macular edema |
| DNA | Deoxyribonucleic acid |
| DR | Diabetic retinopathy |
| DSMC | Data Safety Monitoring Committee |
| EMA | European Medicines Agency |
| EQ-5D-5L | EuroQol 5-dimension 5-level questionnaire |
| ETDRS | Early Treatment Diabetic Retinopathy Study |
| EU | European Union |
| FA | Fluorescein angiography |
| FAF | Fundus autofluorescence |
| FDA | US Food and Drug Administration |
| FFS | Fee-for-service |
| GA | Geographic atrophy |
| GBD | Global Burden of Disease |
| GLP | Good Laboratory Practice |
| GMP | Good Manufacturing Practice |
| HCPCS | Healthcare Common Procedure Coding System |
| HR | Hazard ratio |
| HSD | Honestly significant difference |
| HTRA1 | HtrA serine peptidase 1 gene |
| ICER | Incremental cost-effectiveness ratio |
| IL-31 | Interleukin 31 |
| ILM | Inner limiting membrane |
| IND | Investigational New Drug application |
| IOI | Intraocular inflammation |
| IRF | Intraretinal fluid |
| IV | Intravenous |
| IVI | Intravitreal injection |
| IVT | Intravitreal |
| LIF | Leukemia inhibitory factor |
| LS | Least squares |
| LTFU | Lost to follow-up |
| MCF | Mean cumulative function |
| MHI | Mental Health Inventory |
| miRNA | MicroRNA |
| MMRM | Mixed-effect model for repeated measures |
| MNV | Macular neovascularization |
| MPFS | Medicare Physician Fee Schedule |
| MSVI | Moderate and severe vision impairment |
| NAb | Neutralizing antibody |
| nAMD | Neovascular age-related macular degeneration |
| NEI | National Eye Institute |
| NEI-VFQ-25 | National Eye Institute 25-Item Visual Function Questionnaire |
| NH | Nursing home |
| NHP | Nonhuman primate |
| NI | Noninferiority |
| NICE | National Institute for Health and Care Excellence |
| NVAMD | Neovascular age-related macular degeneration |
| OCT | Optical coherence tomography |
| OCTA | Optical coherence tomography angiography |
| OR | Odds ratio |
| PCV | Polypoidal choroidal vasculopathy |
| PDS | Port delivery system |
| PDT | Photodynamic therapy |
| PI | Principal investigator |
| PlGF | Placental growth factor |
| PMDA | Pharmaceuticals and Medical Devices Agency (Japan) |
| PRIME | Priority Medicines (European Medicines Agency designation) |
| PRN | Pro re nata (as needed) |
| Q8W, Q12W, Q16W, Q20W, Q24W | Every 8, 12, 16, 20, or 24 weeks |
| QALY | Quality-adjusted life year |
| QoL | Quality of life |
| REMS | Risk Evaluation and Mitigation Strategy |
| RMAT | Regenerative medicine advanced therapy |
| RNA | Ribonucleic acid |
| RNAi | RNA interference |
| RO | Retinal vascular occlusion |
| RPE | Retinal pigment epithelium |
| RV | Retinal vasculitis |
| RVO | Retinal vein occlusion |
| RVU | Relative value unit |
| SAE | Serious adverse event |
| SD | Standard deviation |
| SD-OCT | Spectral-domain optical coherence tomography |
| SDF1α | Stromal cell-derived factor 1 alpha |
| SE | Standard error |
| SF-36 | 36-Item Short Form Health Survey |
| SRF | Subretinal fluid |
| SUN | Standardization of Uveitis Nomenclature |
| T&E | Treat-and-extend |
| TEAE | Treatment-emergent adverse event |
| UI | Uncertainty interval |
| US | United States |
| USD | United States dollar |
| VA | Visual acuity |
| VC | Vitreous cells |
| VEGF | Vascular endothelial growth factor |
| VEGF-A, VEGF-B, VEGF-C, VEGF-D | Vascular endothelial growth factor A, B, C, and D |
| vg | Vector genomes |
| VP1 | Viral protein 1 |
| WAC | Wholesale acquisition cost |
| wAMD | Wet age-related macular degeneration |
| WHO | World Health Organization |
| WTP | Willingness to pay |